FDA rejects China-developed Ivonescimab on overall-survival grounds
Summit Therapeutics expects to seek resubmission if year-end head-to-head lung-cancer data prove positive, after the FDA found ivonescimab lacked a statistically significant overall-survival benefit.
TAG K-1065 · 758 words on the filing

Summary of findings
- On the 15th, Summit said the FDA rejected ivonescimab’s US marketing application and requested supplemental documents.
- A March 2025 Lancet report described 398 advanced NSCLC patients: 198 received ivonescimab and 200 received Keytruda.
- Reported progression-free survival was 11.1 months with ivonescimab and 5.8 months with Keytruda.
- The FDA cited no statistically significant overall-survival extension across trials in the US, Canada, Europe and Asia.
- Seventeen late-stage trials are ongoing, completed or planned; a global head-to-head readout is expected by year-end.
By Rebecca Stone
The FDA rejected Summit Therapeutics’ US marketing application for ivonescimab because the global data did not demonstrate a statistically significant extension in overall survival. Summit said on the 15th, local time, that the agency also requested supplemental documents.
Summit acquired US rights to the China-developed drug from Akeso Biopharma, which markets ivonescimab in China. The rejection stops the current application; it does not cancel the development program.
What did the FDA review, and why did it stop?
The application rested on a separate global study of ivonescimab combined with chemotherapy in lung cancer patients who had previously received targeted therapy. According to Summit, data from trials in the United States, Canada, Europe and Asia did not show a statistically significant overall-survival extension.
The FDA’s finding cannot be answered by the China trial’s progression-free survival result. A strong progression endpoint could not substitute for the survival benefit needed to support approval.
Ivonescimab had emerged as a strong competitor to Keytruda; the latter is often cited as the world’s top-selling cancer drug. The FDA action concerned the evidence behind that competitive claim.
How does ivonescimab work, and what did the China trial show?
Ivonescimab is an immune-oncology drug designed to activate immune cells against cancer. It blocks PD-1, an immune checkpoint on immune cells that restrains attack, as Keytruda does, and also inhibits VEGF, a signal supporting new blood vessels when tumors outstrip their oxygen and nutrient supply.
Akeso’s China-based Phase 3 results, published in The Lancet in March 2025, came from a joint team at Shanghai Dongfang Hospital and Tongji University School of Medicine. The study enrolled 398 patients with advanced non-small cell lung cancer, the most common type of lung cancer.
Researchers assigned 198 patients to ivonescimab and 200 to Keytruda. Progression-free survival, the interval from treatment start before progression or death, reached 11.1 months with ivonescimab and 5.8 months with Keytruda.
The reported progression-free survival advantage did not resolve the FDA’s overall-survival objection. The China study and the separate global filing study answered different questions, and their results should not be merged.
Why did Summit say the survival benefit was missed?
Summit attributed the failure to confirm a survival benefit to enrollment delays that shortened the effective study duration. The company submitted additional analyses of patients’ long-term survival outcomes, but those analyses were believed insufficient.
The explanation addresses study conduct, not the cited result: FDA still found no statistically significant survival extension. Neither enrollment dates nor event counts appear in Summit’s explanation as reported, so readers cannot assess how much the delay shortened the study.
Can ivonescimab return to the FDA?
Summit says 17 late-stage trials are ongoing, completed or planned worldwide. Results from a global head-to-head trial against Keytruda in treatment-naïve patients with advanced lung cancer are expected by the end of this year.
If that study produces positive results, Summit expects to reapply for FDA approval. The route back remains conditional: a favorable readout would support another filing, not guarantee acceptance or approval.
Bob Duggan, CEO of Summit Therapeutics, said: “Despite the FDA’s decision, our confidence in the potential of Ivonescimab continues to grow, and our commitment to advancing its development remains unchanged.” That statement commits to continued work, but supplies no filing date or survival target.
What does the rejection mean for the US-China contest?
Some observers interpret the rejection within broader Sino-US competition for life-sciences leadership. The New York Times reported on the 15th, local time, that Chinese pharmaceutical companies face lower regulatory barriers than US counterparts and can push new drug development faster.
Some US lawmakers, investors and corporate executives argue that this environment puts American companies at a significant disadvantage. Historically, the world’s best-selling medicines generally came from US or European research laboratories, while China has long been associated with generic drugs and pharmaceutical ingredients.
A package proposed by the administration of US President Donald Trump would bar US companies and investors from acquiring stakes in Chinese biotechnology firms. Chinese pharmaceutical companies sell US marketing rights to American firms to supply new drugs to US patients; ivonescimab is one such example.
That commercial route gave Summit the US opportunity, but the FDA’s decision turns on trial evidence, not the developer’s nationality or the policy backdrop. The immediate test is the year-end readout, and the next approval case still has to establish an overall-survival benefit.
via FDA industry wire (Google News) (Source)
More from Rebecca Stone
Show full bio
Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
10 articles
Linked filings
- C-4460
- P-9899
- P-6323
- C-6506
- V-1848